Acting FDA head Janet Woodcock has called for an independent probe into potentially inappropriate contacts between FDA staff and a pharma firm, after the agency drew controversy for approving the company’s dementia drug. In a letter published on Friday, the acting Food and Drug Administration commissioner asked Health and Human Services Inspector General Christi Grimm to look into the allegations of misconduct between the regulator and drugmaker Biogen, which were initially brought to light in a report by Stat last month. “There has been significant attention and controversy surrounding the process for the review of Biogen’s biologics
Hence then, the article about fda chief requests probe into own agency s dealings with pharma firm before controversial approval for alzheimer s drug was published today ( ) and is available onRussia Today ( News ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( FDA chief requests probe into own agency’s dealings with pharma firm before controversial approval for Alzheimer’s drug )